GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (NAS:IMNN) » Definitions » Ending Cash Position

Imunon (Imunon) Ending Cash Position : $2.35 Mil (As of Mar. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Imunon Ending Cash Position?

Imunon's Ending Cash Position for the quarter that ended in Mar. 2024 was $2.35 Mil.

Imunon's quarterly Ending Cash Position declined from Sep. 2023 ($12.88 Mil) to Dec. 2023 ($5.84 Mil) and declined from Dec. 2023 ($5.84 Mil) to Mar. 2024 ($2.35 Mil).

Imunon's annual Ending Cash Position declined from Dec. 2021 ($25.59 Mil) to Dec. 2022 ($17.49 Mil) and declined from Dec. 2022 ($17.49 Mil) to Dec. 2023 ($5.84 Mil).

Imunon Ending Cash Position Historical Data

The historical data trend for Imunon's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imunon Ending Cash Position Chart

Imunon Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.88 17.16 25.59 17.49 5.84

Imunon Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.40 6.61 12.88 5.84 2.35

Imunon Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Imunon's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=17.494+-11.655
=5.84

Imunon's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=5.839+-3.492
=2.35

Imunon Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Imunon's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Imunon (Imunon) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (NAS:IMNN) » Definitions » Ending Cash Position
Comparable Companies
RASP SNTI NNVC FRES EDSA PIRS KPRX INTI VAXX CDIO OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
CBO:Germany
Address
997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648
Website
https://www.imunon.com
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
Executives
James E Dentzer director C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Le Goff Corinne director, officer: President and CEO 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Michael H Tardugno officer: Chief Executive Offier 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046-2364
Frederick J. Fritz director C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Kardaras Constantine John officer: Chief Accounting Officer C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE100, LAWRENCEVILLE NJ 08648
Christine A Pellizzari director 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Stacy Lindborg director C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Donald P Braun director C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Alberto R Martinez director C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Jeffrey Wayne Church officer: Chief Financial Officer
Robert W Hooper director C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Andreas Voss director C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Egwu, Inc. Fka Egen, Inc. 10 percent owner 601 GENOME WAY, SUITE 3400, HUNTSVILLE AL 35806
Khursheed Anwer officer: Chief Scientific Officer C/O CELSION CORPORATION, 997 LENOX DRVIE, SUITE 100, LAWRENCEVILLE NJ 08648
Gregory L Weaver director 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107